Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.

Article  CAS  PubMed  Google Scholar 

Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res. 2012;36:1481–9.

Radaelli F, Colombi M, Calori R, et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol. 2007;25:115–20.

Article  PubMed  Google Scholar 

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97.

Article  PubMed  Google Scholar 

Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339–51.

CAS  PubMed  Google Scholar 

Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67:285–91.

Article  CAS  PubMed  Google Scholar 

Gugliotta L, Fiacchini M, et al. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients [abstract]. Blood. 1997;90(suppl 1):348a.

Google Scholar 

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123:656–64.

Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–23.

Article  CAS  PubMed  Google Scholar 

Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica. 2010;95:1038–40.

Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.

Article  CAS  PubMed  Google Scholar 

Thiele J, Kvasnicka HM, Orazi A, et al. Essential thrombocythemia. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 48-50.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

Article  CAS  PubMed  Google Scholar 

•• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. The new 2022 revision of WHO classification that provided updated diagnostic criteria for all BCR::ABL1-negative myeloproliferative neoplasms, including essential thrombocythemia.

•• Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-28. An additional classification which provided updated diagnostic criteria for all BCR::ABL1-negative myeloproliferative neoplasms, integrating clinical-morphological and molecular features.

Kralovics R, Passamonti F, Buser AS, et al. Gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.

Article  CAS  PubMed  Google Scholar 

Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

Article  CAS  PubMed  Google Scholar 

Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J. 2007;13:366–71.

Article  CAS  PubMed  Google Scholar 

Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–83.

Article  CAS  PubMed  Google Scholar 

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–307.

Article  CAS  PubMed  Google Scholar 

Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 2009;94:7–10.

Article  PubMed  PubMed Central  Google Scholar 

Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37:1016–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3: e270.

Article  PubMed  PubMed Central  Google Scholar 

Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.

Article  CAS  PubMed  Google Scholar 

Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Eng J Med. 2013;369:2379–90.

Article  CAS  Google Scholar 

Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Eng J Med. 2013;369:2391–405.

Article  CAS  Google Scholar 

Cattaneo D, Croci GA, Bucelli C, et al. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021;11:637116.

Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–5.

Article  CAS  PubMed  Google Scholar 

Fabris S, Cattaneo D, Salerio S, et al. Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. Thromb Res. 2022;210:67-9.

Gangat N, Wassie E, Lasho T, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015;94:31–6.

Article  CAS  PubMed  Google Scholar 

Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocytemia with substantially different clinical course and outcomes. Blood. 2014;123:1544–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen CC, Gau JP, Chou HJ, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014;93:2029–36.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89:E121–4.

Article  CAS  PubMed  Google Scholar 

Perez Encinas MM, Sobas M, Gomez-Casares MT, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: a multicentre collaborative study. Eur J Haematol. 2021;106:371–9.

Article  CAS  PubMed  Google Scholar 

Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431–8.

Article  CAS  PubMed  Google Scholar 

Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786–90.

Article  PubMed  Google Scholar 

Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645–51.

Article  PubMed  Google Scholar 

Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417–21.

Article  CAS  PubMed  Google Scholar 

Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.

Article  PubMed  Google Scholar 

Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313–20.

Article  CAS  PubMed  Google Scholar 

Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

Article  PubMed  PubMed Central  Google Scholar 

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599–613.

Article  CAS  PubMed  Google Scholar 

Ferrari A, Stark D, Peccatori FA, et al. Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open. 2021;6: 100096.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.

Article